Thrombolytic Science International (TSI) is a clinical-stage, privately-held vascular medicine and biotechnology company founded in 2006 in Cambridge, Mass., based on discoveries made in the Vascular Research Laboratory at Beth Israel Deaconess Medical Center by TSI cofounder and Harvard Medical School Professor, Victor Gurewich, M.D.
TSI’s mission is to develop new generation products to treat thrombotic diseases. TSI is currently developing a new-generation clot-dissolving therapy with the first novel mechanism of action in 20 years for stroke and other thrombotic diseases. TSI’s technology is based upon pioneering earlier work on prourokinase (proUK) by Dr. Gurewich. The primary component of TSI’s thrombolytic therapy is a rationally designed mutant of prourokinase, mproUK, invented by Dr. Jian-ning Liu.
TSI controls several granted patent families and patent filings in the U.S. and Europe, including, but not limited to, the treatment of stroke and other exclusively licensed rights from Beth Israel Deaconess Medical Center, Boston.